<DOC>
	<DOC>NCT00754221</DOC>
	<brief_summary>This is a study to investigate the long-term safety and effectiveness [S,S]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.</brief_summary>
	<brief_title>Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>Male or female of any race, at least 18 years of age Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites) Completed preceding doubleblind randomized, controlled trial Patients with other severe pain (eg, Diabetic Peripheral Neuropathy and PostHerpetic Neuralgia) that may confound assessment or self evaluation of the pain associated with fibromyalgia Patients with any autoimmune rheumatic disorder, nonfocal rheumatic disease (other than fibromyalgia), active infection, or untreated endocrine disorder A current or recent diagnosis (last 6 months) or episode of major depressive disorder, dysthymia and/or uncontrolled depression History of mania, hypomania, other psychotic disorder, or current mood disorder with psychotic features</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Phase 3, safety study, [S,S]-Reboxetine, Fibromyalgia</keyword>
</DOC>